Securities Registration: Employee Benefit Plan (s-8)
February 26 2021 - 4:29PM
Edgar (US Regulatory)
As
filed with the Securities and Exchange Commission on February 26, 2021
Registration
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-8
REGISTRATION
STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Provention
Bio, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
81-5245912
|
(State
or other jurisdiction of
incorporation or organization)
|
|
(I.R.S.
Employer
Identification
No.)
|
55
Broad Street, 2nd Floor
Red
Bank, New Jersey 07701
(Address
of Principal Executive Offices) (Zip Code)
Amended and Restated Provention Bio,
Inc. 2017 Equity Incentive Plan
(Full
title of the plan)
Ashleigh
Palmer
Chief
Executive Officer
Provention
Bio, Inc.
55
Broad Street, 2nd Floor
Red
Bank, New Jersey 07701
(908)
336-0360
(Name,
address and telephone number, including area code, of agent for service)
with
copies to:
Christopher
Comeau
Thomas
J. Danielski
Ropes
& Gray LLP
800
Boylston Street
Boston,
Massachusetts 02199
(617)
951-7000
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer [X]
|
Accelerated
filer [ ]
|
Non-accelerated
filer [ ]
|
Smaller
reporting company [ ]
|
|
Emerging
growth company [ ]
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
[ ]
CALCULATION
OF REGISTRATION FEE
Title
of securities to be registered
|
|
Amount
to be registered(1)
|
|
|
Proposed
maximum offering price per share(2)
|
|
|
Proposed
maximum aggregate offering price(2)
|
|
|
Amount
of registration fee(2)
|
|
Common Stock, $0.0001 par
value
|
|
|
2,270,353
|
(3)
|
|
$
|
13.63
|
|
|
$
|
30,944,911.39
|
|
|
$
|
3,376.09
|
|
(1)
|
Pursuant
to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement
includes any additional shares of the registrant’s common stock that may be issued pursuant to anti-dilution provisions
contained in the Amended and Restated Provention Bio, Inc. 2017 Equity Incentive Plan (the “2017 Plan”).
|
|
|
(2)
|
Pursuant
to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the
high and low prices of the registrant’s common stock on the Nasdaq Global Select Market on February 25, 2021.
|
|
|
(3)
|
Represents
2,270,353 shares of the registrant’s common stock that were automatically added to the shares authorized for issuance
under the 2017 Plan on January 1, 2021 pursuant to an “evergreen” provision contained in the 2017 Plan. The “evergreen”
provision provides that on each January 1st from January 1, 2019 through January 1, 2028, the number of shares
of common stock available for issuance under the 2017 Plan will automatically increase annually in an amount equal to the
lesser of (i) the difference between (x) eighteen percent (18%) of the total number of shares of common stock outstanding,
on a fully diluted basis, on December 31st of the preceding calendar year, and (y) the total number of shares of common stock
reserved under the 2017 Plan on December 31st of such preceding calendar year and (ii) the number of shares determined by
the registrant’s board of directors.
|
EXPLANATORY
NOTE
This
Registration Statement is being filed to register an additional 2,270,353 shares of the registrant’s common stock for issuance
under the Amended and Restated Provention Bio, Inc. 2017 Equity Incentive Plan. Pursuant to General Instruction E to Form S-8,
the registrant incorporates by reference, except to the extent supplemented, amended or superseded by the information set forth
herein, into this Registration Statement the entire contents of its Registration Statement on Form S-8 (File No. 333-226814) filed
with the Securities and Exchange Commission on August 13, 2018, its Registration Statement on Form S-8 (File No. 333-230400) filed
with the Securities and Exchange Commission on March 19, 2019 and its Registration Statement on Form S-8 (File No. 333-237113)
filed with the Securities and Exchange Commission on March 12, 2020.
PART
II
INFORMATION
REQUIRED IN THE REGISTRATION STATEMENT
Item
8. Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it
meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the City of Red Bank, State of New Jersey, on February 26, 2021.
|
|
Provention
Bio, Inc.
|
|
|
|
|
By:
|
/s/
Ashleigh Palmer
|
|
|
Ashleigh
Palmer
|
|
|
Chief
Executive Officer
|
POWER
OF ATTORNEY
Each
person whose signature appears below constitutes and appoints Ashleigh Palmer, Andrew Drechsler and Heidy King-Jones, and each
of them acting individually, his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution,
for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective
amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority
to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents
and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents,
or their substitutes, may lawfully do or cause to be done by virtue hereof.
*
* * *
Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the
capacities and on the date indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/
Ashleigh Palmer
|
|
Chief
Executive Officer and Director
|
|
February
26, 2021
|
Ashleigh
Palmer
|
|
(Principal
Executive Officer)
|
|
|
|
|
|
|
|
/s/
Andrew Drechsler
|
|
Chief
Financial Officer (Principal
|
|
February
26, 2021
|
Andrew
Drechsler
|
|
Financial
and Accounting Officer)
|
|
|
|
|
|
|
|
/s/
Jeffrey Bluestone, PhD
|
|
Director
|
|
February
26, 2021
|
Jeffrey
Bluestone, PhD
|
|
|
|
|
|
|
|
|
|
/s/
Avery Catlin
|
|
Director
|
|
February
26, 2021
|
Avery
Catlin
|
|
|
|
|
|
|
|
|
|
/s/
Sean Doherty
|
|
Director
|
|
February
26, 2021
|
Sean
Doherty
|
|
|
|
|
|
|
|
|
|
/s/
John Jenkins, MD
|
|
Director
|
|
February
26, 2021
|
John
Jenkins, MD
|
|
|
|
|
|
|
|
|
|
/s/
Wayne Pisano
|
|
Director
|
|
February
26, 2021
|
Wayne
Pisano
|
|
|
|
|
|
|
|
|
|
/s/
Nancy Wysenski
|
|
Director
|
|
February
26, 2021
|
Nancy
Wysenski
|
|
|
|
|
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Jul 2023 to Jul 2024